Medlab owns and runs an Office of the Gene Technology Regulator (OGTR) approved PC2 Biologic facility in NSW, Australia.
This is the primary site for research projects.
Presently we are involved in early phase drug discovery in 5 key areas:
Medlab has multiple patents pending on our products:
Product |
Jurisdiction |
Description |
Application Number |
Filling Date |
Status |
|---|---|---|---|---|---|
|
T2Biotic |
Australia |
Probiotic composition and uses thereof for obesity-related disorders |
2015258769 |
11/5/15 |
Filed |
|
T2Biotic |
Australia (innovation) |
Probiotic composition and uses thereof for obesity-related disorders |
2-17101478 |
30/10/17 |
Granted |
|
NRGBiotic |
Australia |
Probiotic combinations and uses thereof |
2015202755 |
21/5/15 |
Granted |
|
NRGBiotic |
Australia (innovation) |
Probiotic combinations and uses thereof |
2015100928 |
6/8/15 |
Granted |
|
EnBiotic |
Australia (Innovation) |
Probiotic and enzyme containing compositions and uses thereof |
2015100952 |
17/7/15 |
Granted |
|
CKD |
Australia |
Probiotic compositions and uses thereof (i) |
2018903306 |
4/9/17 |
Provisional application filed Complete application due 5 Sep 2019 |
|
Cannabinoids |
Australia |
Probiotic compositions and uses thereof (ii) |
2018903305 |
4/9/17 |
Provisional application filed Complete application due 5 Sep 2019 |
|
Orotate |
Australia |
Treatment for depression and depressive disorders |
2015337800 |
28/10/15 |
Filed |
|
Orotate |
Canada |
Treatment for depression and depressive disorders |
2964971 |
28/10/15 |
Filed |
|
Orotate |
Europe |
Treatment for depression and depressive disorders |
15854029.4 |
28/10/15 |
Filed |
|
Orotate |
New Zealand |
Treatment for depression and depressive disorders |
731151 |
28/10/15 |
Filed |
|
Orotate |
Singapore |
Treatment for depression and depressive disorders |
11201703193X |
28/10/15 |
Under Examination |
|
Orotate |
United States |
Treatment for depression and depressive disorders |
15/523271 |
28/10/15 |
Filed |
|
ORSbiotic |
Australia (Innovation) |
Probiotic compositions for rehydration |
2016100500 |
2/5/16 |
Granted |
|
GastroDaily |
Australia (Innovation) |
Yeast-containing compositions for gastrointestinal health |
2016100499 |
2/5/16 |
Granted |
|
W8Biotic |
Australia (Innovation) |
Probiotic composition for weight management |
2016100501 |
2/5/16 |
Granted |
|
Nanocelle |
Australia |
Transmucosal and transdermal delivery systems |
PCT/US2016/020468 |
2/3/16 |
Filed |
|
Nanocelle |
Canada |
Transmucosal and transdermal delivery systems |
2978179 |
2/3/16 |
Filed |
|
Nanocelle |
Europe |
Transmucosal and transdermal delivery systems |
16759418.3 |
2/3/16 |
Filed |
|
Nanocelle |
New Zealand |
Transmucosal and transdermal delivery systems |
735138 |
2/3/16 |
Filed |
|
Nanocelle |
Singapore |
Transmucosal and transdermal delivery systems |
11201707068X |
2/3/16 |
Examination Requested |
|
Nanocelle |
United States |
Transmucosal and transdermal delivery systems |
15/555038 |
2/3/16 |
Filed |
|
Nanocelle |
Hong Kong |
Transmucosal and transdermal delivery systems |
18103321.4 |
8/3/2018 |
Filed |
|
API Degradation |
Australia |
Protection of plant extracts and compounds from degradation |
PCT/AU2017/050430 |
11/5/17 |
Filed 30 month national phase entry deadline 11 Nov 2018 |
|
T2Biotic - Intestinal Microbiota |
Australia |
microbiota in pre-diabetes and type 2 diabetes |
2017904443 |
1/11/17 |
provisional application fixed Complete application due 1 Nov 18 |
|
T2Biotic -SCFA |
Australia |
Modulation of intestinal microbiota in pre-diabetes and type 2 diabetes |
2017904444 |
1/11/17 |
Provisional application filed. complete application due 1 Nov 2018 |
|
Hydrogel Formulation |
Australia |
NanocCelle Bacteria |
In draft |
11/5/16 |
provisional specification proposed |